Current treatment approaches for diffuse large B-cell lymphoma

References

• Fisher R I, Gaynor E R, Dahlberg S, Oken M M, Grogan T M, Mize E M, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Sehn L H, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109: 1857–1861
   PubMed Web of Science ®Google Scholar
• Rosenwald A, Wright G, Chan W C, Connors J M, Campo F, Fisher R I, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large – B-cell lymphoma. N Engl J Med 2002; 346: 1937–1947
   PubMed Web of Science ®Google Scholar
• Henrickson S E, Hartmann E M, Ott G, Rosenwald A. Gene expression profiling in malignant lymphomas. Adv Exp Med Biol 2007; 593: 134–146
   PubMed Web of Science ®Google Scholar
• Hans C P, Weisenburger D D, Greiner T C, Gascoyne R D, Delabie J, Ott G, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004; 103: 275–282
   PubMed Web of Science ®Google Scholar
• Haarer C F, Roberts R A, Frutiger Y M, Grogan T M, Rimsza L M. Immunohistochemical classification of de novo, transformed, and relapsed diffuse large B-cell lymphoma into germinal center B-cell and nongerminal center B-cell subtypes correlates with gene expression profile and patient survival. Arch Pathol Lab Med 2006; 130: 1819–1824
   PubMed Web of Science ®Google Scholar
• de Jong D, Rosenwald A, Chhanabhai M, Gaulard P, Klapper W, Lee A, et al. Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications – a study from the Lunenburg Lymphoma Biomarker Consortium. J Clin Oncol 2007; 25: 805–812
   PubMed Web of Science ®Google Scholar
• Coiffier B. Increasing chemotherapy intensity in aggressive lymphomas: a renewal?. J Clin Oncol 2003; 21: 2457–2459
   PubMed Web of Science ®Google Scholar
• Held G, Schubert J, Reiser M. Pfreundschuh M, German High-Grade Non-Hodgkin-Lymphoma Study Group. Dose-intensified treatment of advanced-stage diffuse large B-cell lymphomas. Semin Hematol 2006; 43: 221–229
   PubMed Web of Science ®Google Scholar
• Shipp M A, Neuberg D, Janicek M, Canellos G P, Shulman J N. High-dose CHOP as initial therapy for patients with poor-prognosis aggressive non-Hodgkin's lymphoma: a dose-finding pilot study. J Clin Oncol 1995; 13: 2916–2923
   PubMed Web of Science ®Google Scholar
• Blayney D W, LeBlanc M L, Grogan T, Gaynor E R, Chapman R A, Spiridonidis C H, et al. Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the Southwest Oncology Group (SWOG 9349). J Clin Oncol 2003; 21: 2466–2473
   PubMed Web of Science ®Google Scholar
• Tilly H, Lepage E, Coiffier B, Blanc M R, Bosly A, et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003; 102: 4284–4289
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller A C, Rübe C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood 2004; 104: 634–641
   PubMed Web of Science ®Google Scholar
• Haioun C, Lepage E, Gisselbrecht C, Salles G, Coiffier B, Brice P, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol – a Groupe d'Etude des Lymphomes de l'Adulte Study. J Clin Oncol 2000; 18: 3025–3030
   PubMed Web of Science ®Google Scholar
• van Imhoff G W, van der Holt B, Mackenzie M A, Van't Veer M B, Wijermans P W, Ossenkoppele G J, et al. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40. J Clin Oncol 2005; 23: 3793–3801
   PubMed Web of Science ®Google Scholar
• Coiffier B, Haioun C, Ketterer N, Engert A, Tilly H, Ma D, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998; 92: 1927–1932
   PubMed Web of Science ®Google Scholar
• Vose J M, Link B K, Grossbard M L, Czuczman M, Grill-Lopez A, Gilman P, et al. Phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. J Clin Oncol 2001; 19: 389–397
   PubMed Web of Science ®Google Scholar
• Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235–242
   PubMed Web of Science ®Google Scholar
• Habermann T M, Weller E A, Morrison V A, Gascoyne R D, Cassileth P A, Cohn J B, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006; 24: 3121–3127
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Trümper L, Osterborg A, Pettengell R, Trneny M, Imrie K, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7: 379–391
   PubMed Web of Science ®Google Scholar
• Sehn L H, Donaldson J, Chhanabhai M, Fitzgerald C, Gill K, Klasa R, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005; 23: 5027–5033
   PubMed Web of Science ®Google Scholar
• Feugier P, Van Hoof A, Sebban C, Sola-Celigny P, Bouabdallah R, Fermé C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005; 23: 4117–4126
   PubMed Web of Science ®Google Scholar
• Coiffier B, Feugier P, Mounier N, Franchi-Rezgui P, Van Den Neste E, Macro M, et al. Journal of Clinical Oncology 2007; 8009, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement)
   Google Scholar
• Pfreundschuh M, Trümper L, Kloess M, Schmits R, Feller A C, Rübe C, et al. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood 2004; 104: 626–633
   PubMed Web of Science ®Google Scholar
• Spicer S, Smith P, Maclennan K, Hoskin P, Hancock B, Linch D, et al. Long-term follow-up of patients treated with radiotherapy alone for early stage histologically aggressive non-Hodgkin's Lymphoma. British J Cancer 2004; 90: 1151–1155
   PubMed Web of Science ®Google Scholar
• Miller T P, Dahlberg M S, Cassady J R, Adelstein D J, Spier C M, Grogan T M, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localised intermediate- and high-grade non-Hodgkin's Lymphoma. N Engl J Med 1998; 339: 21–26
   PubMed Web of Science ®Google Scholar
• Miller T P, LeBlanc M, Spier C, et al. CHOP alone compared to CHOP versus radiotherapy for early stage aggressive Non-Hodgkin's lymphomas: update of the Southwest Oncology Group (SWOG) randomized trial (abstract). Blood 2001; 98: 724
   Web of Science ®Google Scholar
• Horning S J, Weller E, Kim K M, Earle J D, O'Connell M J, Habermann T M, et al. Chemotherapy with or without radiotherapy in limited-stage diffuse aggressive non-Hodgkin's lymphoma: Eastern Cooperative Oncology Group Study 1484. J Clin Oncol 2004; 22: 3032–3038
   PubMed Web of Science ®Google Scholar
• Reyes F, Lepage E, Ganem G, Molina T J, Brice P, Coiffier B, et al. ACVBP versus CHOP plus radiotherapy for localised aggressive lymphoma. N Engl J Med 2005; 352: 1197–1205
   PubMed Web of Science ®Google Scholar
• Bonnet C, Fillet G, Mournier N, Ganem G, Molina T J, Thiéblemont C, et al. CHOP alone compare with CHOP plus radiotherapy for localised aggressive lymphoma in elderly patients: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2007; 25: 787–792
   PubMed Web of Science ®Google Scholar
• Avilés A, Delgado S, Nambo M J, Alatriste S, Díaz-Maqueo J C. Adjuvant radiotherapy to sites of precious bulky disease in patients with stage IV diffuse large cell lymphoma. Int J Radiat Oncol Biol Phys 1194; 30: 799–803
   Google Scholar
• Moser E C, Kluin-Nelemans H C, Carde P, Meerwaldt J H, Tirelli U, Aleman B M, et al. Impact of involved field radiotherapy in partial response after doxorubicin-based chemotherapy for advanced aggressive non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys 2006; 66: 1168–1177
   PubMed Web of Science ®Google Scholar
• Spaepen K, Stroobants S, Dupont P, Vandenberghe P, Thomas J, de Groot T, et al. Early restaging positron emission tomography with 18 F-fuorodeoxyglucose predicts outcome in patients with aggressive non-Hodgkin's Lymphoma. Ann Oncol 2002; 13: 1356–1363
   PubMed Web of Science ®Google Scholar
• Kahn S T, Flowers C, Lechowicz M J, Hollenbach K, Johnstone P A. Value of PET restaging after chemotherapy for non-Hodgkin's lymphoma: implications for consolidation radiotherapy. Int J Radiat Oncol Biol Phys 2006; 66: 961–965
   PubMed Web of Science ®Google Scholar
• Hoskin P J, Smith P, Falk S, Benstead K, Illidge T, Qian W, et al. Radiation dose in non-Hodgkin's lymphoma: preliminary results of a UK NCRN randomised trial. Ann Oncol 2005; 16(Suppl 5)59
   Google Scholar
• Laskar S, Bahl G, Muckaden M A, Gupta S, Bakshi A, Gujral S, et al. Primary diffuse large cell B-cell lymphoma of the tonsil. Is a higher radiation dose required?. Cancer 2007, Published online 20 Jun 2007
   PubMed Web of Science ®Google Scholar
• Laskar S, Muckaden M A, Bahl G, de S, Nair R, Gupta S, Bakshi A, et al. Primary non-Hodgkin's lymphoma of the nasopharynx: prognostic factors and outcome of 113 Indian patients. Leuk Lymphoma 2006; 47: 2132–2139
   PubMed Web of Science ®Google Scholar
• Czuczman M S, Weaver R, Alkuzweny B, Berlfein J, Grill-López A J, et al. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin's lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol 2004; 22: 4711–4716
   PubMed Web of Science ®Google Scholar
• Coiffier B. State-of-the-art therapeutics: diffuse large B-cell lymphoma. J Clin Oncol 2005; 23: 6387–6393
   PubMed Web of Science ®Google Scholar
• Pfreundschuh M, Schubert J, Ziepert M, Schmits R, Mohren M, Lengfelder E, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol. Feb, 2008; 9(2)105–116 Epub 2008 Jan 15
   PubMed Web of Science ®Google Scholar
• Greb A, Bohlius J, Trelle S, Schiefer D, De Souza C A, Gisselbrecht C, et al. High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysis. Cancer Treat Rev. Jun, 2007; 33(4)338–346, Epub 2007 Apr 2
   PubMed Web of Science ®Google Scholar
• Milpied N, Deconinck E, Gaillard F, Delwail V, Foussard C, Berthou C, et al. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support. N Engl J Med 2004; 350: 1287–1295
   PubMed Web of Science ®Google Scholar
• Gordon L I, Molina A, Witzig T, Emmanouilides C, Raubtischek A, Darif M, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: long-term follow-up of a phase 1/2 study. Blood 2004; 103: 4429–4431
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Illidge T, Huglo D, Martinelli G, Paganelli G, Zinzani P L, et al. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood 2007; 110: 54–58
   PubMed Web of Science ®Google Scholar
• Wilson W H, Gutierrez M, O'Connor P, Frankel S, Jaffe E, Chabner B A, et al. The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R. Semin Oncol 2002; 29: 41–47
   PubMed Web of Science ®Google Scholar